
Reimagining Pharmaceutical Drug Development with a Biomimetic Platform
Already funded by the Kuni Foundation This project takes preclinical testing that might last 10 weeks at a cost of $45,000 down to 12 days
Already funded by the Kuni Foundation This project takes preclinical testing that might last 10 weeks at a cost of $45,000 down to 12 days
Already funded by an anonymous donor The goal of this project is to optimize a selective TrkB inhibitor for ligand-dependent neuroblastoma.
Already funded by CureMEC and an anonymous donor The goals of this multi-year research program aim to answer the fundamental questions about Myoepithelial Carcinoma (MEC)
Already funded by the Megan’s Mission Foundation Rhabdomyosarcoma and soft tissue sarcomas are among the five greatest causes of death from childhood cancer and are
Already funded by the Megan’s Mission Foundation Childhood muscle cancer is rare but also unique among cancers – rhabdomyosarcoma not only mimics normal muscle stem
Already funded by the Rucker Collier Foundation! Sclerosing Epithelioid Fibrosarcoma (SEF) is a rare soft tissue sarcoma of children, teenagers and adults that can also
Already funded by the National Cancer Institute/National Institutes of Health! Alveolar rhabdomyosarcoma (aRMS) is generally not survivable when metastatic. However, this disease does respond to
Already funded by the Macy Easom Cancer Research Foundation The Macy Easom Research Foundation and cc-TDI have been longstanding partners with a series of milestones:
Already funded by the Kuni Foundation This project takes preclinical testing that might last 10 weeks at a cost of $45,000 down to 12 days
Already funded by an anonymous donor The goal of this project is to optimize a selective TrkB inhibitor for ligand-dependent neuroblastoma.
Already funded by CureMEC and an anonymous donor The goals of this multi-year research program aim to answer the fundamental questions about Myoepithelial Carcinoma (MEC)
Already funded by the Megan’s Mission Foundation Rhabdomyosarcoma and soft tissue sarcomas are among the five greatest causes of death from childhood cancer and are
Already funded by the Megan’s Mission Foundation Childhood muscle cancer is rare but also unique among cancers – rhabdomyosarcoma not only mimics normal muscle stem
Already funded by the Rucker Collier Foundation! Sclerosing Epithelioid Fibrosarcoma (SEF) is a rare soft tissue sarcoma of children, teenagers and adults that can also
Already funded by the National Cancer Institute/National Institutes of Health! Alveolar rhabdomyosarcoma (aRMS) is generally not survivable when metastatic. However, this disease does respond to
Already funded by the Macy Easom Cancer Research Foundation The Macy Easom Research Foundation and cc-TDI have been longstanding partners with a series of milestones:
EIN: 46-5759569
cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)
Copyright 2024 – Children’s Cancer Therapy Development Institute